Compare Crispr Therapeutics AG (CRSP) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Invesco WilderHill Clean Energy ETF — how do they compare? Crispr Therapeutics AG trades at $50.52 (market cap $4.97B), while Invesco WilderHill Clean Energy ETF trades at $34.85. The key difference: Invesco WilderHill Clean Energy ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | PBW | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Sector/Thematic |
52-Week High | $76.78 | $46.99 |
52-Week Low | $44.34 | $22.23 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
PBW (Invesco WilderHill Clean Energy ETF) trades at $34.00, down 3.46% with a bearish technical signal from moving averages. The ETF shows oversold conditions with RSI readings below 30, while clean energy sector news highlights both volatility and growth potential driven by energy security concerns and data center demand. Recent articles note PBW's 34% year-to-date gains but caution about rate cycle sensitivity.
Outlook remains mixed with technical weakness offset by clean energy tailwinds. Investment opportunity lies in global energy transition trends, but risks include interest rate sensitivity and sector volatility. The ETF's performance is heavily influenced by macroeconomic factors rather than individual company fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
